<div id="readability-page-1"><div>By Billy Gray Novartis said it expected a key profitability metric to decline this year in large part due to increased competition in the U.S. from generic drug competitors. The Swiss pharma major said Wednesday that it expects its core operating profit--one of its preferred metrics, which strips out exceptional items--for 2026 to decline by a low single digit. It expects low single-digit sales growth this year. Novartis said in the performance update that in 2026, it would face the largest drug-patent expiry headwind in its history. Three blockbuster treatments--Entresto, Promacta and Tasigna--lost U.S. patent exclusivity toward the middle of last year, which the group said was the primary catalyst of its guidance toward a short-term profitability fall. Increased competition from generic competitors would generate a roughly $4 billion negative impact in 2026, Harry Kirsch, Novartis's chief financial officer, said in a call with reporters. Fourth-quarter sales for the heart-failure treatment Entresto fell 45% on year at constant currency, to $1.25 billion, while Promacta sales for the period plunged 63% at constant exchange rates, to $226 million. Net sales in the fourth quarter fell 1% at constant currency compared with the prior-year period, to $13.34 billion, the company said. Still, Novartis reiterated that it expects sales to grow through 2030 at a compound annual rate of 5% to 6%. J.P. Morgan analysts said that would lead to a 9% consensus-estimate beat for 2030 sales that would require a number of successful treatment candidates in the pipeline. Changes to U.S. drug pricing to most-favored-nations levels didn't have a material effect on 2026 guidance, Chief Executive Vas Narasimhan said. The company said core operating profit for the year grew to $21.89 billion from $19.49 billion for the year prior, on sales that rose to $54.53 billion from $50.32 billion. Analysts polled by Visible Alpha had forecast $21.85 billion in core operating profit and $54.82 billion in sales. Write to Billy Gray at william.gray@wsj.com (END) Dow Jones Newswires02-04-26 0638ET</div></div>

Novartis forecasts a decline in core operating profit for 2026 due to increased competition from generic drugs in the U.S., expecting a low single-digit drop. The company faces significant patent expirations, particularly for blockbuster drugs like Entresto and Promacta, which have already seen substantial sales declines. Despite this, Novartis anticipates a 5-6% annual sales growth through 2030. Fourth-quarter sales fell slightly to $13.34 billion, but core operating profit rose to $21.89 billion, slightly above analyst expectations.

marketscreener

NOVARTIS AG

Direxion S&P Biotech Bear 3X

Penghua SSE STAR Biology and Medicine ETF

iShares US Pharma

GF CSI HK Innovative Drugs Industry ETF(QDII)

Proshares Ultra Nasdaq Biotech

VanEck Biotech ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Yinhua CSI Innovative Drugs Industry ETF

ALPS Medical Breakthrough

China Merchants CSI Biotechnology Theme ETF

Health Care Select Sector SPDR

E Fund Hang Seng SCHK Innovative Drug ETF

VG Health

E Fund CSI Biotechnology Theme ETF

Guotai CSI Bio-medicine ETF

ChinaAMC CSI Biotechnology Theme ETF

Invesco Nasdaq Biotechnology ETF

Tianhong CNI BIOMEDICINE ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

E Fund CSI 300 Health Care ETF

iShares Biotechnology ETF

China Southern Hang Seng Biotech ETF(QDII)

SPDR S&P Biotech

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Penghua CSI HK Connect Health Care Composite ETF

Bosera Hang Seng Health Care ETF(QDII)

Minsheng Royal CSI Biotechnology Theme ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Invesco Biotechnology & Genome ETF

ICBCCS SSE STAR Biology and Medicine ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Ark Genomic Revolution ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

诺发集团

First Trust NYSE Arca Biotech Index Fd

ChinaAMC SSE Health Care ETF Initiating Fund

iShares Global Healthcare

Huaan Hang Seng Biotech ETF

Novartis Forecasts Profitability Hit From Generic Drug Competition in U.S. -- Update